TricValve® Transcatheter Bicaval Valves System
Today P+F Products + Features GmbH announced that the first implantation of its Breakthrough technology, the TricValve® Transcatheter Bicaval Valves System, was recently performed under the guidance of Samir Kapadia MD, Interventional Cardiologist and Chairman, Dept. of Cardiovascular Medicine and Rishi Puri MD PhD, Interventional Cardiologist, at Cleveland Clinic, Ohio, USA. The successful procedure in a patient with longstanding severe tricuspid regurgitation and right heart failure was performed under conscious sedation and TTE guidance.
“It’s a great pleasure and honor to perform the first Tricvalve implantation in US at such an outstanding institution as the Cleveland Clinic together with the amazing team of Drs. Samir Kapadia and Rishi Puri,” stated Dr. Katharina Kiss, CEO of the company.
The TricValve® Transcatheter Bicaval Valves is a system of two self-expanding biological valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux.
“For our patients with tricuspid regurgitation and systemic congestion with no other options, this procedure can provide a new treatment option, ” states Dr. Samir Kapadia.
“We look forward to further studying this device in the future and testing it versus medical therapy.” according to Dr. Rishi Puri.
Among others, Dr. Rishi Puri performs consulting activities on behalf of P+F Products + Features GmbH.
About the TricValve® Transcatheter Bicaval Valves System
The two dedicated bioprostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve.
They are especially intended for use in patients at extreme risk or who are inoperable for open heart surgical therapy. P+F uses exclusivly it’s proprietary “Dry Pericardium”, which enables the TricValve® Transcatheter Bicval Valves System to come fully pre-mounted, thus facilitating the use of this innovative device in daily clinical practice.
Today P+F Products + Features GmbH announced that the first implantation of its Breakthrough technology, the TricValve® Transcatheter Bicaval Valves System, was recently performed under the guidance of Samir Kapadia MD, Interventional Cardiologist and Chairman, Dept. of Cardiovascular Medicine and Rishi Puri MD PhD, Interventional Cardiologist, at Cleveland Clinic, Ohio, USA. The successful procedure in a patient with longstanding severe tricuspid regurgitation and right heart failure was performed under conscious sedation and TTE guidance.
“It’s a great pleasure and honor to perform the first Tricvalve implantation in US at such an outstanding institution as the Cleveland Clinic together with the amazing team of Drs. Samir Kapadia and Rishi Puri,” stated Dr. Katharina Kiss, CEO of the company.
The TricValve® Transcatheter Bicaval Valves is a system of two self-expanding biological valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux.
“For our patients with tricuspid regurgitation and systemic congestion with no other options, this procedure can provide a new treatment option, ” states Dr. Samir Kapadia.
“We look forward to further studying this device in the future and testing it versus medical therapy.” according to Dr. Rishi Puri.
Among others, Dr. Rishi Puri performs consulting activities on behalf of P+F Products + Features GmbH.
About the TricValve® Transcatheter Bicaval Valves System
The two dedicated bioprostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve.
They are especially intended for use in patients at extreme risk or who are inoperable for open heart surgical therapy. P+F uses exclusivly it’s proprietary “Dry Pericardium”, which enables the TricValve® Transcatheter Bicval Valves System to come fully pre-mounted, thus facilitating the use of this innovative device in daily clinical practice.
